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Incidence and modes of onset of early reinitiation
of atrial fibrillation after successful internal
cardioversion, and its prevention by intravenous
sotalol
H-F Tse, C-P Lau, G M Ayers
Abstract
Objectives—To study the incidence and
mode of onset of early reinitiation of atrial
fibrillation (ERAF) following successful
internal cardioversion of chronic atrial
fibrillation, and to determine the eVects of
sotalol in the prevention of ERAF.
Design—The incidence and modes of
onset of ERAF and the acute eVects of
intravenous sotalol in the prevention of
ERAF were studied retrospectively.
Setting—Electrophysiology laboratory at
a university teaching hospital.
Patients—64 patients, mean (SD) age 62
(10) years, who underwent internal car-
dioversion of chronic atrial fibrillation
(mean duration of atrial fibrillation 31
(39) months).
Main outcome measures—ECGs and
intracardiac electrograms recorded dur-
ing the internal cardioversion of atrial
fibrillation using 3/3 ms biphasic, R wave
synchronised shocks.
Results—52 patients (81%) had successful
electrical cardioversion, and 20 (31%) of
these had ERAF during the procedure.
There was no clinical predictor for the
occurrence of ERAF.Fifty eight episodes of
ERAF were observed. Five ERAF episodes
(9%) had preceding bradycardia and 53
(91%) of these were triggered by atrial pre-
mature beats with normal preceding heart
rate. Atrial premature beats that reiniti-
ated atrial fibrillation had a shorter cou-
pling interval (333 (43) ms v 396 (100),
p < 0.001) and a lower prematurity index
(0.44 (0.11) v 0.55 (0.14), p < 0.001) than
those that did not reinitiate atrial fibrilla-
tion. Repeated shock delivery and increas-
ing the defibrillation energy did not
prevent ERAF. Intravenous sotalol infusion
decreased the numbers of atrial premature
beats and prolonged their coupling inter-
val, and prevented ERAF after repeated
defibrillation in 83% of patients with ERAF.
Conclusions—ERAF is a significant clinical
problem after successful internal cardiover-
sion of chronic atrial fibrillation, and was
observed in up to 31% of patients. In most
episodes, ERAF was triggered by short cou-
pling atrial premature beats with preceding
normal heart rate. Intravenous sotalol was
eVective in preventing ERAF in most cases.
(Heart 1999;82:319–324)
Keywords: atrial fibrillation; low energy cardioversion;
sotalol
Low energy internal cardioversion has been
shown to be very eVective in converting atrial
fibrillation.1–6 This procedure requires only
mild sedation and is more eVective than exter-
nal cardioversion.7 8 Thus the use of low energy
internal cardioversion may result in restoration
of sinus rhythm in a greater number of patients.
However, unstable sinus rhythm followed by
early reinitiation of atrial fibrillation (ERAF)
shortly after successful electrical cardioversion
was observed in up to 13–36% of patients.9–11 It
could significantly limit the number of patients
with successful clinical termination of atrial
fibrillation. A rational approach to preventing
ERAF may depend on a better understanding
of its incidence and modes of onset. Further-
more, the role of class III antiarrhythmic agents
in preventing the spontaneous reinitiation of
atrial fibrillation after successful cardioversion
remains largely unknown. The purpose of the
present study was to investigate the incidence
and clinical variables that predict the occur-
rence of ERAF shortly after successful internal
cardioversion of chronic atrial fibrillation, the
modes of onset of ERAF, and the eYcacy of a
class III agent, sotalol, in the prevention of
ERAF.
Methods
PATIENTS
We carried out a retrospective study of 64 con-
secutive patients with chronic atrial fibrillation
of at least one month’s duration who under-
went internal cardioversion. A detail clinical
examination was performed and a complete
medical history was taken. Routine 12 lead
ECG, 24 hour Holter monitoring, chest x ray,
routine laboratory and thyroid tests, and trans-
thoracic and transoesophageal echocardio-
graphy were assessed in all patients. Patients
with the following conditions were excluded
from study: reversible causes of atrial fibrilla-
tion, moderate to severe valvar heart disease,
unstable angina or recent myocardial infarc-
tion, class III or IV heart failure, contraindica-
tion to sotalol (asthma, chronic obstructive
pulmonary disease, significant sinus nodal or
conduction system dysfunction, or a previous
adverse reaction to a â blocker), or evidence of
left atrial thrombus. No study patient had been
receiving any class I, III, or IV antiarrhythmic
drugs for more than five half lives, or amiodar-
one for longer than three months.
All patients gave written informed consent
before the procedure, and the protocol was
approved by the ethics committee of the
University of Hong Kong.
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ANTICOAGULATION PROTOCOL
All patients were treated with oral anticoagu-
lants, using warfarin to achieve an international
normalised ratio (INR) of 2–3 for at least three
weeks before the procedure. Warfarin was dis-
continued two days before the procedure and
was replaced with an intravenous heparin infu-
sion. The heparin infusion was stopped four
hours before and restarted after the procedure.
The INR was checked daily and immediately
before the procedure, and the minimum INR
value considered safe for venous puncture was
less than 1.5. Warfarin was restarted after the
procedure and heparin infusion was discontin-
ued when the therapeutic INR of 2–3 was
achieved.
STUDY PROTOCOL
Details of the internal cardioversion procedure
in our laboratory have been described
previously.3 In brief, low energy biatrial shocks
were delivered through two transvenously
introduced defibrillation catheters. One of
these catheters was positioned in the coronary
sinus and one in the anterolateral right atrium.
In 36 patients, a pair of temporary 6 F decapo-
lar catheters (Elecath, New Jersey, USA) was
used. In the remaining 28 patients, two custom
built spring coil electrodes were used (Perim-
eter 7107 and 7023, InControl Inc, Redmond,
Washington, USA). The right atrial catheter
served as the cathode and the coronary sinus
catheter as the anode. Two additional 6 F cath-
eters were positioned, one in the right ventricu-
lar apex (for shock synchronisation and post-
shock pacing) and one in high right atrium (for
recording the atrial electrogram and pacing);
both were advanced from the right femoral
vein. The defibrillation catheters were con-
nected to a custom made external atrial
defibrillator (XAD, InControl Inc) capable of
delivering an R wave synchronised biphasic
shock waveform (3/3 ms) with a leading edge
voltage that could be programmed between 10
and 400 V.
Patients were sedated with intravenous
midazolam (0.05 mg/kg) and pethidine (0.5
mg/kg), and additional doses were given as
required. Starting with a 20 V test shock, R
wave synchronised shocks were delivered start-
ing at 180 V and increasing in steps of 40 V
until sinus rhythm was restored, or the until
two at the highest output of 400 V had been
delivered. Between unsuccessful defibrillation
attempts, at least two minutes were allowed to
elapse before the next shock was applied.
During the study, two surface ECGs (lead II
and V6), a bipolar high right atrium and
ventricular electrogram, and arterial blood
pressure were recorded simultaneously. ERAF
was defined as the occurrence of spontaneous
reinitiation of a sustained atrial fibrillation epi-
sode after successful internal cardioversion.
Following successful internal cardioversion,
the rhythm was monitored for up to five
minutes to look for any episodes of ERAF and
their mode of onset. Where ERAF were
triggered by atrial premature beats, their char-
acteristics were studied and compared with
those not triggered by atrial premature beats.
We determined the following:
+ coupling interval of atrial premature beats
(atrial to atrial premature beats)
+ mean atrial cycle length of three to five con-
secutive preceding beats
+ the prematurity index (atrial premature beat
cycle length/preceding rhythm cycle length)
using a high right atrium endocardial
electrogram
+ the density of atrial premature beats
(number of atrial premature beats/min).
In those patients with ERAF, a repeat
defibrillation shock at the initially successful
energy was given. If the atrial fibrillation still
recurred, up to two high energy shocks at the
maximum voltage of 400 V were tested in some
patients. For patients who still had ERAF, an
intravenous infusion of sotalol (1.5 mg/kg) over
30 minutes was given, and defibrillation shocks
were repeated using the same step up protocol,
starting at 180 V. In those patients who failed
cardioversion at baseline, intravenous sotalol
was also given to determine whether it could
reduce the atrial defibrillation requirement.
The eVect of sotalol on the atrial defibrillation
threshold has been reported before.12 Oral
sotalol 160–320 mg/day was given to those
patients who had successful cardioversion and
were maintained in sinus rhythm after the pro-
cedure.
STATISTICAL METHODS
Continuous data are presented as mean (SD).
Statistical analysis was performed by analysis of
variance, Mann–Whitney U test, or Fisher
exact test, as appropriate, and between group
comparisons were performed by a multiple
Bonferroni test. A probability (p) value of
< 0.05 was considered statistically significant.
Results
PATIENT CHARACTERISTICS
The 64 patients included 45 men and 19
women, aged 36 to 80 years, mean 62 (10)
years. The duration of atrial fibrillation ranged
from 1 to 192 months,mean 31 (39).Mean left
ventricular ejection fraction was 58 (10)%
(range 35% to 75%) and mean left atrial diam-
eter was 4.4 (0.6) cm (range 3.1 to 5.5 cm).
Underlying heart disease was present in 36
patients (56%), including hypertension (23),
treated thyroid heart disease (5), mild valvar
heart disease (4), dilated cardiomyopathy (3),
and congenital heart disease (1).
EFFICACY OF INTERNAL CARDIOVERSION AND
INCIDENCE OF ERAF
These results are summarised in fig 1. Before
sotalol, successful internal cardioversion of
atrial fibrillation was achieved in 52 patients
(81%) at a mean threshold of 325 (60) V and a
mean energy of 3.92 (1.4) J. However, 20
patients (31%) had ERAF shortly after suc-
cessful cardioversion and failed to maintain
stable sinus rhythm. Two patients had only one
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episode of ERAF and remained in stable sinus
rhythm after repeated shock delivery. In the
remaining 18 patients with repeated episodes
of ERAF, increasing the shock energy to maxi-
mum output of 400 V was tested in 14 patients
but failed to prevent recurrence of atrial fibril-
lation in any of them. Twelve patients (19%)
had unsuccessful cardioversion despite two
defibrillation shocks at maximum output of
400 V. The clinical characteristics of these
patients are given in table 1. There were no sig-
nificant diVerences between the patients with
and without reinitiation of ERAF, and those in
whom sinus rhythm could not be restored, with
respect to age, sex ratio, left ventricular ejection
fraction, left atrial size, use of â blockers or
digitalis, and absence of underlying heart
disease. Patients with stable sinus rhythm and
ERAF had a comparable duration of atrial
fibrillation, whereas patients with unsuccessful
cardioversion had a significantly longer dura-
tion of atrial fibrillation (p < 0.05).
MODE OF ONSET OF ERAF
Before drug testing, 58 episodes of spontane-
ous atrial fibrillation reinitiation were observed
at a mean duration of 10 (4) seconds after
internal cardioversion. Five episodes of ERAF
(9%), in two patients, were initiated after a
period of bradycardia (with a mean atrial cycle
length > 1200 ms) (fig 2A). In 53 ERAF
episodes (91%), atrial fibrillation was reiniti-
ated by atrial premature beats after a short
period of organised electrical activity without
preceding bradycardia (fig 2B). In 19 of these
ERAF episodes in five patients, the episodes
were preceded by a long–short sequence of
their preceding atrial rhythm cycle length
(defined where the shorter cycle length is
< 75% of the longer one) (fig 2C). Further-
more, in 16 ERAF episodes in six patients, the
atrial premature beats that reinitiated the atrial
fibrillation seemed to be repetitive in nature:
these atrial premature beats had a similar P
wave morphology and a consistent cycle length
with less than 10 ms variability, suggesting a
similar origin for all.
In patients with ERAF, atrial premature
beats without triggering atrial fibrillation were
also observed. There was no significant diVer-
ence in the preceding atrial cycle length
between atrial premature beats associated with
or not associated with reinitiation of atrial
fibrillation. Atrial premature beats that resulted
in reinitiation of atrial fibrillation had a shorter
beat to beat coupling interval (333 (43) ms v
396 (100) ms, p < 0.001) and greater prematu-
rity with a lower prematurity index than those
that did not result in reinitiation of atrial fibril-
lation (0.44 (0.11) v 0.55 (0.14), p < 0.001).
EFFICACY OF INTRAVENOUS SOTALOL IN
PREVENTING ERAF
An intravenous sotalol infusion (at a mean dose
of 124 (32) mg) was given to 18 patients who
had persistent ERAF despite repeated shock
delivery. None of them was converted to sinus
rhythm after sotalol administration, and re-
peated internal cardioversion was performed.
There was no significant change in the atrial
defibrillation requirement after sotalol admin-
istration compared with baseline (327 (56) v
310 (24) V, p > 0.05). Sotalol was eVective in
preventing reinitiation of atrial fibrillation in 15
patients (83%) and in maintaining stable sinus
rhythm. After sotalol infusion, the density of
atrial premature beats decreased significantly
compared with baseline, at 4.4 (3.8) v 14.7
(11) atrial premature beats/min, p < 0.0001.
Furthermore, the cycle length of the preceding
atrial rhythm (1055 (155) ms v 801 (207) ms,
p < 0.001) and the atrial premature beat
coupling interval (401 (54) ms v 333 (43) ms,
p < 0.001) were also prolonged after sotalol
infusion compared with baseline. In those
patients who failed cardioversion at baseline,
Figure 1 Flow chart showing the outcome of patients after low energy internal
cardioversion of atrial fibrillation (AF) and the results of treatment for spontaneous
reinitiation of atrial fibrillation by repeated defibrillation, intravenous sotalol and atropine,
and atrial pacing. SR, sinus rhythm.
Internal cardioversion
AF
n = 64
Spontaneous AF
reinitiation
n = 20 (31%)
Repeated
cardioversion
n = 20
Intravenous sotalol
and repeated cardioversion
n = 30
High energy
cardioversion
n = 14
Atrial pacing (n = 1)
or
Atropine (n = 1)
SR
n = 58 (91%)
SR
n = 32 (50%)
AF
n = 12 (19%)
n = 12*
n = 4
n = 2
n = 34
n = 14
n = 14
n = 2
n = 2
n =
15
n = 7*
n = 5*
n = 1
AF
n = 6 (9%)
Table 1 Clinical characteristics of study patients according to the result of internal
cardioversion
Successful
cardioversion
Early reinitiation of
atrial fibrillation
Failed
cardioversion
Number (%) 32 (50) 20 (31) 12 (19)
Age (years) 61 (11) 64 (9) 65 (9)
Sex (M:F) 20:12 15:5 10:2
Left atrial diameter (mm) 44 (6) 43 (7) 44 (7)
Left ventricular ejection fraction 59 (12) 58 (8) 57 (12)
Threshold (V) 324 (56) 326 (54) –
Energy (J) 3.95 (1.24) 4.06 (1.45) –
Drug treatment (n)
â Blocker 12 8 6
Digitalis 7 2 2
None 13 10 4
No heart disease (n) 14 9 5
Duration of atrial fibrillation (months) 25 (37)* 28 (44)* 51 (31)
Values are mean (SD).
*p < 0.05 v failed cardioversion.
Reinitiation of AF after internal cardioversion 321
 on 13 November 2006 heart.bmj.comDownloaded from 
seven of 12 had successful cardioversion after
sotalol infusion and none of these had ERAF.
In the two patients with ERAF associated
with bradycardia, sotalol alone was not eVec-
tive in preventing recurrence of atrial fibrilla-
tion but worsened the bradycardia, with long
sinus pauses after cardioversion. Elimination of
this bradycardia after cardioversion seemed to
be eVective in preventing further ERAF. Thus
the administration of intravenous atropine
before repeated defibrillation resulted in sinus
rhythmwithout sinus pauses or ERAF in one of
the patients. In the other patient, atrial pacing
at a cycle length of 500 ms was started imme-
diately after defibrillation and was eVective in
preventing recurrence of further atrial fibrilla-
tion. Both of these patients remained in stable
sinus rhythm thereafter. One patient failed to
maintain in sinus rhythm owing to persistent
ERAF, despite administration of sotalol and
repeated defibrillation (fig 1).
COMPLICATIONS
Overall, 1402 R wave synchronised shocks
were delivered to the 64 patients without ven-
tricular proarrhythmia or acute complication.
Cardiac enzymes including creatine kinase and
its isoenzyme CK-MB measured before and
after defibrillation did not show any significant
change. One patient developed symptomatic
persistent junctional bradycardia after sotalol
which required temporary pacing for two days.
Two patients experienced heart failure with
oral sotalol and required drug termination.
Discussion
EFFICACY OF INTERNAL CARDIOVERSION AND
INCIDENCE OF ERAF
Restoration of sinus rhythm is the preferred
goal of treatment in patients with persistent
atrial fibrillation, as it should eliminate symp-
toms, improve exercise capacity, and reduce
thromboembolic complications, and as it might
improve survival. However, for patients with
atrial fibrillation of prolonged duration, electri-
cal cardioversion with external shocks requires
higher energies and has a low success rate.13
Recently, internal cardioversion has been
shown to be highly eVective in conversion of
atrial fibrillation, even where external cardio-
version has failed.1–8 The results of our study
have confirmed the eYcacy and safety of low
energy internal cardioversion in restoring sinus
rhythm, with a success rate of 81% in patients
with prolonged atrial fibrillation before cardio-
version (mean duration 31 (39) months).
Recurrences of atrial fibrillation are com-
monly observed after successful cardioversion.
In previous studies, unstable sinus rhythm fol-
lowed by ERAF recurrence occurred in
13–36% of patients within minutes after
successful electrical cardioversion, either exter-
nal or internal.9–11 In the present study we
showed that up to 31% of patients with chronic
atrial fibrillation without pretreatment with
antiarrhythmic agents had spontaneous ERAF
shortly after cardioversion. We found that the
occurrence of ERAF was not related to the
previous arrhythmia duration or to any of the
clinical variables (age, sex ratio, left atrial size,
left ventricular ejection fraction, defibrillation
energy and voltage, use of â blockers and digi-
talis, or the type of heart disease). Repeated
cardioversion was only eVective at preventing
ERAF in 10% of patients, and ERAF could not
Figure 2 DiVerent modes of onset of early reinitiation of atrial fibrillation (AF). (A) AF
reinitiation preceding by bradycardia (mean atrial cycle length = 1240 ms). (B) AF was
reinitiated an atrial premature beat (APB) after a short period of organised electrical
activity. Note the normal heart rate preceding the onset of APB. (C) AF was reinitiated by
APB with preceding long/short cycles. HRA, high right atrium.
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B
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be prevented by increasing the energy of the
defibrillation shock.
MODES OF ONSET OF ERAF
It is well known that a spontaneous atrial fibril-
lation episode is usually initiated by atrial pre-
mature beats.14 15 Previous studies using Holter
recording have shown that atrial premature
beats that initiated atrial fibrillation had a
shorter coupling interval and greater prematu-
rity than isolated atrial premature beats that
did not initiate atrial fibrillation.16–18 Consistent
with these findings, recent studies10 11 have
demonstrated that ERAF following internal
cardioversion was usually preceded by an atrial
premature beat with a short coupling interval,
and occurred within the first minutes after car-
dioversion. However, the characteristics of car-
diac rhythm preceding the onset of ERAF
remain unclear. Observations on the heart rate,
initiation sequence, and coupling interval of
the initiating atrial premature beats may allow
treatment strategies to be tailored appropri-
ately. Suppression of ERAF has important
implications for the use of temporary low
energy internal cardioversion and may require
more frequent treatment with an implantable
atrial defibrillator.19
In the present study, the onset of ERAF epi-
sodes and the characteristics of the atrial
premature beats were recorded using a surface
ECG and an intra-atrial electrogram. In about
10% of patients, the ERAF episodes were pre-
ceded by a long sinus pause. The cause of the
bradycardia may be underlying sinoatrial
disease or electrical remodelling of the sinus
node by atrial fibrillation.20 It may be further
aggravated by shock induced sinus node
suppression.3 During bradycardia, the escape
atrial ectopic activity, together with the pause
dependent conduction abnormalities, may
trigger the onset of atrial fibrillation.18 How-
ever, in the majority of episodes (90%), atrial
fibrillation was reinitiated by atrial premature
beats with a short coupling interval which were
not preceded by bradycardia or tachycardia.
Consistent with previous studies,10 11 16–18 atrial
premature beats that reinitiated atrial fibrilla-
tion had a significantly shorter cycle length and
greater prematurity than those that did not.We
observed that in up to 30% of patients the
onset of atrial fibrillation was preceded by a
long–short atrial sequence. A recent study has
shown the occurrence of a preceding long–
short atrial sequence was strongly associated
with development of atrial fibrillation even in
patients without a history of this arrhythmia.21
It has been postulated that long–short cardiac
sequences increase the dispersion of myocar-
dial refractoriness and their vulnerability for
reentrant arrhythmias.22 23 Furthermore, in one
third of our patients, the atrial premature beats
that initiated atrial fibrillation had a very simi-
lar P wave morphology and consistent cycle
length, suggesting the presence of a similar or
focal origin. These patients might have a focal
source of atrial fibrillation, and more detailed
endocardial mapping may be useful to identify
the origin of these atrial premature beats.23
EFFECTS OF INTRAVENOUS SOTALOL
Previous studies9–11 suggested that administer-
ing antiarrhythmic drugs before cardioversion
might prevent early recurrence of atrial fibrilla-
tion. Limited data show that intravenous
flecainide may acutely suppress ERAF.10 How-
ever, the role of class III antiarrhythmic drugs
in the acute suppression of ERAF remains
unclear. In the present study, we observed that
intravenous sotalol could suppress ERAF
acutely in the majority of patients (83%). Fur-
thermore, of those patients who initially failed
cardioversion and had successful cardioversion
after sotalol infusion, none had ERAF. This
also suggested that pretreatment with sotalol
before cardioversion could prevent ERAF.
Although the mechanism of action of sotalol in
suppressing reinitiation of atrial fibrillation
remains unclear, our results suggest that it
might prevent ERAF by suppressing the onset
of atrial premature beats (probably by its â
blocking eVect) and prolonging the coupling
interval of atrial premature beats (possibly a
class III eVect). Both decreasing the numbers
of atrial premature beats and prolonging their
coupling interval may reduce the likelihood
that such beats will encounter the vulnerable
atrial period and this will help prevent reinitia-
tion of atrial fibrillation. However, in those
patients with ERAF preceding by bradycardia,
sotalol caused further worsening of the brady-
cardia and could not prevent reinitiation of
atrial fibrillation.
CLINICAL IMPLICATIONS
A rational approach to preventing ERAF may
depend on a careful evaluation of the pattern of
onset. Although our data suggest that intra-
venous sotalol can eVectively suppress ERAF
acutely in the majority of patients, other
non-pharmacological treatments may also be
useful in preventing ERAF. Thus in patients
with bradycardia dependent onset of atrial
fibrillation, atrial support pacing may reduce
the occurrence of atrial fibrillation.24 As shown
in the present study, the prevention of brady-
cardia or sinus pauses by atrial pacing or atro-
pine was eVective at preventing these atrial
fibrillation episodes. Furthermore, whether
atrial pacing prevents ERAF by eliminating the
long–short rhythm cycle that precedes the
onset of atrial fibrillation or by suppressing the
atrial premature beats which might precipitate
atrial fibrillation requires further study. In a
subset of patients, the atrial fibrillation epi-
sodes were reinitiated by atrial premature beats
with a consistent coupling interval and similar
P wave morphology, suggesting the presence of
a focal source of atrial fibrillation. This type of
focal atrial fibrillation may be amenable to
radiofrequency ablation of the focus, as shown
in recent studies.25 26
STUDY LIMITATIONS
Owing to the retrospective nature of the study
and the fact that only two surface ECGs and a
high right atrial electrogram were recorded
during the procedure, the origin of the atrial
premature beats that reinitiated the atrial
fibrillation could not be determined. More
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detailed mapping of the onset of atrial fibrilla-
tion and the origin of the atrial premature
beats, using multiple endocardial catheters or
new mapping techniques, might provide a bet-
ter understanding of the mechanisms of ERAF.
Although our observations suggested that sota-
lol might be eVective in preventing ERAF, it is
impossible to draw firm conclusions because
the study was not randomised. Nevertheless,
before sotalol infusion all patients with ERAF
underwent repeated cardioversions that were
followed by reinitiation of atrial fibrillation.
This suggests that the observed eVect after
sotalol administration was attributable to its
use. Furthermore, our observations that sotalol
suppressed atrial premature beats and that
none of the patients in whom cardioversion was
successful only after sotalol infusion had ERAF
provide further indirect evidence to support
the eYcacy of sotalol in preventing ERAF.
CONCLUSIONS
We have shown that ERAF occurred in up to
31% of patients with chronic atrial fibrillation
after successful internal cardioversion. This is a
significant clinical problem which limits the
number of patients having successful clinical
termination of sustained atrial fibrillation. It
has implications for the use of both temporary
and permanent transvenous defibrillation in
treating atrial fibrillation. ERAF is usually pre-
ceded by the occurrence of atrial premature
beats, although the cardiac sequences preced-
ing their onset seem to be heterogeneous.
Intravenous sotalol eVectively suppressed
ERAF in the majority of patients. The use of
other antiarrhythmic agents and the role of
non-pharmacological treatment for the preven-
tion of ERAF after internal cardioversion
require further investigation.
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